Medicine and public health

On Thursday 19 September 2024 at 6.30pm, the Crash team was delighted to welcome Priscille Sauvegrain for a conference on medical practices in maternal health in France and the role played by racial categories. The meeting was hosted by Judith Soussan. 

In this paper, Jacob Burns analyzes MSF's activities in the provision of social support.  In the introduction, he suggests a rough outline of different ‘social’ problems that MSF has turned to between the 1980s and the 2010s. The second part of the paper is a report of a field visit conducted in October – November 2023 to Goma, DRC.

This article is an addition to Issue 25 of Humanitarian Alternatives "Food crisis: what role for humanitarian actors?", published in March 2024.

On Thursday 29 February at 6.00pm, we welcomed sociologists Théo Boulakia and Nicolas Mariot, the authors of "L’Attestation. Une expérience d’obéissance de masse, printemps 2020".

To address the political, economic and legal barriers to patients' access to life-saving treatments, MSF created, in 1999, the Access Campaign (the Campaign for Access to Essential Medicines). In these videos, Jean-Hervé Bradol, doctor and crash study director, answers questions from Andrea Bussotti (MSF-France Operational Communication Manager). In the light of the historical background of the early days of the Access Campaign, he analyses the medico-operational context of the Campaign today and asks himself the question of its objectives.

On 3rd and 4th February 2022, the CRASH organised a workshop aimed at the leaders, operational managers and members of MSF France, to shed light on the current debates on access to medicines, and to determine together which issues are the most relevant to resolve. In preparation for this workshop, the CRASH asked experts external to MSF to explain their vision of today’s pharmaceutical industry system, with subjects that ranged from pre-development to distribution, and included patents and quality-related issues.

Based on a reflection regarding how patient rights have changed, in France in particular, Fabrice Weissman discusses humanitarian medicine’s shortcomings in that regard and proposes several avenues for improvement at MSF.  This text was originally posted on MSF’s associative website, The Souk.

On 3rd and 4th February 2022, the CRASH organised a workshop aimed principally at the directors and operational managers of MSF Operational Centre Paris (OCP) to reflect on current debates, and to determine which elements of the discussion would be the most relevant to resolve to support the advancement of MSF OCP’s operational projects. Is access to medicines the same issue today as it was when MSF first became interested in the mid-1990s? Rather than just concentrating on the obstacles to accessing medicines, should the debate be broadened to encompass what are now called ‘health products’ or even further, towards access to care and thus largely structural problems of human resources, financing, or the absence of national health insurance policies?

“Death is an extremely grave non-emergency; its only treatment is mourning”. That is how doctor Miguel Martinez Almoyna introduces his concept of emergency. The retired 92-year-old anaesthesiologist played an active role in creating France’s SMUR, and later SAMU, emergency medical systems. Still quite active overseas (in Brazil and Mexico), where he has exported the French pre-hospital model, he explains his approach to régulation médicale, whose purpose is to guide patients to the medical services their condition requires while offering a range of responses corresponding to different degrees of severity and urgency.

Humanitarian medicine is intented for marginalized people, hit by a crisis or deprived of access to medical care. This book helps us understand how the specificity of humanitarian medicine stems from real-life situations, more than from the medical act in itself.

This article was published on December 22nd, 2021, in the Journal of Humanitarian Affairs (Issue 3, Volume 3).
Despite a concerted international effort in recent decades that has yielded significant progress in the fight against HIV/AIDS, the disease continues to kill large numbers of people, especially in certain regions like rural Ndhiwa district in Homa Bay County, Kenya. Although there is still no definitive cure or vaccine, UNAIDS has set an ambitious goal of ending the epidemic by 2030, specifically via its 90-90-90 (treatment cascade) strategy – namely that 90 per cent of those with HIV will know their status; 90 per cent of those who know their status will be on antiretroviral therapy and 90 per cent of those on antiretroviral therapy will have an undetectable viral load. These bold assumptions were put to the test in a five-year pilot project launched in June 2014 by Médecins Sans Frontières (MSF) and Kenya’s Ministry of Health in Ndhiwa district, where an initial NHIPS 1 study by Epicentre (MSF’s epidemiology centre) in 2012 revealed some of the world’s highest HIV incidence and prevalence, and a poor “treatment cascade”. Six years later a new Epicentre study, NHIPS 2, showed that the 90-90-90 target had been more than met. What explains this ‘success’? And given the still-high incidence, is it truly a success? What follows is an interview on the political, scientific, and operational challenges of the Ndhiwa project with MSF Deputy Director of Operations Pierre Mendiharat and physician Léon Salumu, Head of MSF France Kenya programs, conducted by Elba Rahmouni.